Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years

Type of publication: Academic publication
Disease: Neuromuscular disease

Authors:

Irene Pulido-Valdeolivas, Magí Andorrà, David Gómez-Andrés, Kunio Nakamura, Salut Alba-Arbalat, Erika J. Lampert, Irati Zubizarreta, Sara Llufriu, Eloy Martinez-Heras, Elisabeth Solana, Nuria Sola-Valls, María Sepulveda, Ana Tercero-Uribe, Yolanda Blanco, Anna Camos-Carreras, Bernardo Sanchez-Dalmau, Pablo Villoslada, Albert Saiz & Elena H. Martinez-Lapiscina


Understanding of the role of focal inflammation, a treatable feature, on neuro-axonal injury, is paramount to optimize neuroprotective strategy in MS. To quantify the impact of focal inflammatory activity on the rate of neuro-axonal injury over the MS course. We quantified the annualized rates of change in peripapillary retinal nerve fiber layer, ganglion cell plus inner plexiform layer (GCIPL), whole-brain, gray matter and thalamic volumes in patients with and without focal inflammatory activity in 161 patients followed over 5 years. We used mixed models including focal inflammatory activity (the presence of at least one relapse or a new/enlarging T2-FLAIR or gadolinium- enhancing lesion), and its interaction with time adjusted by age, sex, use of disease-modifying therapies and steroids, and prior optic neuritis. The increased rate of neuro-axonal injury during the first five years after onset was more prominent among active patients, as reflected by the changes in GCIPL thickness (p = 0.02), whole brain (p = 0.002) and thalamic volumes (p < 0.001). Thereafter, rates of retinal and brain changes stabilized and were similar in active and stable patients. Focal inflammatory activity is associated with neurodegeneration early in MS which reinforces the use of an early intensive anti-inflammatory therapy to prevent neurodegeneration in MS.


Published: 7 August 2020
Journal: Scientific reports, volume 10, issue 13333 (2020)

Link: doi.org/10.1038/s41598-020-70255-z

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission


“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern